4//SEC Filing
Gillies Hunter 4
Accession 0001415889-24-013630
CIK 0001798749other
Filed
May 16, 8:00 PM ET
Accepted
May 17, 7:10 PM ET
Size
10.9 KB
Accession
0001415889-24-013630
Insider Transaction Report
Form 4
Gillies Hunter
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-17$2.14/sh+4,000$8,560→ 9,602 total - Sale
Common Stock
2024-05-17$21.07/sh−3,914$82,452→ 5,688 total - Sale
Common Stock
2024-05-17$21.86/sh−86$1,880→ 5,602 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-17−4,000→ 11,324 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (4,000 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
- [F2]Includes 2,351 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.605 to $21.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.
Documents
Issuer
Aerovate Therapeutics, Inc.
CIK 0001798749
Entity typeother
Related Parties
1- filerCIK 0001868997
Filing Metadata
- Form type
- 4
- Filed
- May 16, 8:00 PM ET
- Accepted
- May 17, 7:10 PM ET
- Size
- 10.9 KB